Pharmaceutical compositions and methods of making on demand solid dosage formulations
A pharmaceutical composition and methods for using the pharmaceutical composition are disclosed. The pharmaceutical composition may include a therapeutically effective amount of one or more antiviral active pharmaceutical ingredients and a pharmaceutically acceptable excipient. The pharmaceutical composition may be a solid dosage form, wherein the solid dosage form provides sustained release of the antiviral active pharmaceutical ingredient when administered as a vaginal or rectal insert.
1. A pharmaceutical composition comprising:
a. a therapeutically effective amount of one or more antiviral active pharmaceutical ingredients; and
b. one or more pharmaceutically acceptable excipient, wherein said one or more pharmaceutically acceptable excipient comprises:
a binder in an amount from about 0.5% to about 8% by weight;
a water-soluble disintegrating agent in an amount from about 0.5% to about 4% by weight; and
a bioadhesive polymer in an amount from about 5% to about 30% by weight,
wherein said pharmaceutical composition provides a therapeutically effective amount of the antiviral active pharmaceutical ingredient to vaginal or rectal mucosa when administered topically, wherein the bioadhesive polymer is selected from the group consisting of: PEG 4000, PEG 6000 and PEG 8000.
2. A pharmaceutical composition comprising:
a. a therapeutically effective amount of one or more antiviral active pharmaceutical ingredients; and
b. one or more pharmaceutically acceptable excipient, wherein said one or more pharmaceutically acceptable excipient comprises:
a binder in an amount from about 0.5% to about 8% by weight;
a water-soluble disintegrating agent in an amount from about 0.5% to about 4% by weight; and
a bioadhesive polymer in an amount from about 5 % to about 30 % by weight,
wherein said pharmaceutical composition provides sustained release of said antiviral active pharmaceutical ingredient when administered as a vaginal or rectal insert, wherein the bioadhesive polymer is selected from the group consisting of: PEG 4000, PEG 6000 and PEG 8000.
3. A solid dosage form comprising:
a. a therapeutically effective amount of one or more antiviral active pharmaceutical ingredients; and
b. one or more pharmaceutically acceptable excipient, wherein said one or more pharmaceutically acceptable excipient comprises:
a binder in an amount from about 0.5% to about 8% by weight;
a water-soluble disintegrating agent in an amount from about 0.5% to about 4% by weight; and
a bioadhesive polymer in an amount from about 5% to about 30% by weight,
wherein said solid dosage form exhibits a mucoadhesive detachment force of at least 0.1 N when measured in accordance with test method described herein with porcine vaginal mucosa, wherein the bioadhesive polymer is selected from the group consisting of: PEG 4000, PEG 6000 and PEG 8000.
4. The solid dosage form of claim 3 , wherein the dosage form comprises about 1.5% to about 15% by weight of antiviral active pharmaceutical ingredients.
5. The solid dosage form of claim 3 , wherein said one or more active pharmaceutical ingredients comprise an NRTI and an integrase inhibitor.
6. The solid dosage form of claim 3 , wherein said one or more active pharmaceutical ingredients comprise tenofovir alafenamide fumarate (TAF) and elvitegravir (EVG).
7. The solid dosage form of claim 6 , wherein said tenofovir alafenamide fumarate (TAF) is present in an amount from about 2% to 8% TAF as free base and said elvitegravir (EVG) is present in an amount from about 1.6% to 4.8%.
8. The solid dosage form of claim 3 , wherein said one or more pharmaceutically acceptable excipient comprises povidone.
9. The solid dosage form of claim 8 , wherein said povidone comprises povidone K29/32, povidone K30 or a mixture thereof.
10. The solid dosage form of claim 3 , wherein said one or more pharmaceutically acceptable excipient comprises poloxamer 188 present in an amount from 0.5 to 4% by weight.
11. The solid dosage form of claim 3 , wherein said one or more pharmaceutically acceptable excipient comprises lactose present in an amount from about 25% to 75% by weight.
12. The solid dosage form of claim 3 , wherein said one or more pharmaceutically acceptable excipient comprises a sugar alcohol present in an amount from about 5% to 30% by weight.
13. The solid dosage form of claim 12 wherein said sugar alcohol is selected from the group consisting of mannitol, glycerol, erythritol, xylitol, sorbitol, isomalt, maltitol, lactitol, and mixtures thereof.
14. The solid dosage form of claim 3 , wherein said one or more pharmaceutically acceptable excipient comprises PEG present in an amount from about 5 to 30% by weight.
15. The solid dosage form of claim 3 , wherein said one or more pharmaceutically acceptable excipient comprises a lubricant selected from the group consisting of magnesium stearate, stearic acid, sodium stearyl fumarate, glycerol monostearate, colloidal silicon dioxide, talc, calcium stearate and mixtures thereof in the concentration ranging from 0.2-4% by weight.
16. The solid dosage form of claim 3 , wherein said one or more pharmaceutically acceptable excipient comprises a hydrophilic excipient.
17. The solid dosage form of claim 3 wherein:
said one or more active pharmaceutical ingredients comprises TAF and EVG;
said binder comprises povidone;
said water soluble disintegrating agent comprises poloxamer 188; and
said bioadhesive polymer comprises PEG 8000.
18. The solid dosage form of claim 3 , wherein the dosage form further comprises an antibiotic.
19. The solid dosage form of claim 18 , wherein the antibiotic is selected from the group consisting of tetracyclines, macrolides, lincosamides, nitroimidazoles and mixtures thereof.
20. The solid dosage form of claim 18 , wherein the antibiotic is selected from the group consisting of doxycycline, doxycycline hyclate, doxycycline anhydrous, doxycycline monohydrate, azithromycin, clindamycin, metronidazole, tinidazole, secnidazole and mixtures thereof.
21. A method for treating or preventing a viral infection in a subject comprising administering the solid dosage form in accordance with claim 3 to the subject.
22. The method of claim 21 wherein the viral infection is selected from the group consisting of HIV, HSV and HBV.
23. The method of claim 21 further comprising treating another infection.
24. The method of claim 23 wherein the another infection is selected from the group consisting of chlamydia, gonorrhea, bacterial vaginosis, trichomoniasis and syphilis.
25. The method of claim 23 wherein the viral infection is selected from the group consisting of HIV, HSV and HBV.